about
A systematic screen of FDA-approved drugs for inhibitors of biological threat agentsMicrobiota and Neurological Disorders: A Gut Feeling.A tribute to David Triggle.Epigenetic Treatment of Neurodegenerative Disorders: Alzheimer and Parkinson Diseases.Epigenetic Treatment of Neuropsychiatric Disorders: Autism and Schizophrenia.Epigenetic Treatment of Persistent Viral Infections.Bioprotective carnitinoids: lipoic acid, butyrate, and mitochondria-targeting to treat radiation injury: mitochondrial drugs come of age.Cholinergic agents: effect of methyl substitution in a series of arecoline derivatives on binding to muscarinic acetylcholine receptors.Gut Microbiota and Salivary Diagnostics: The Mouth Is Salivating to Tell Us Something.Efficient syntheses of benzothiazepines as antagonists for the mitochondrial sodium-calcium exchanger: potential therapeutics for type II diabetes.Mitochondrial drugs come of age.Epigenetic Treatment of Neurodegenerative Ophthalmic Disorders: An Eye Toward the Future.17α-estradiol: a less-feminizing estrogenReview of the effects of 17α-estradiol in humans: a less feminizing estrogen with neuroprotective potentialEthical Issues in the Biotechnology and Pharmaceutical IndustriesPharmaceutical applications of biotechnology: Promise and reality. Editorial overviewA silica gel plate-based qualitative assay for acetylcholinesterase activity: A mass method to screen for potential inhibitorsN6-Cycloalkyladenosines. Potent, A1-selective adenosine agonistsA New Approach to Treating Neurodegenerative Otologic DisordersPeptides 2020: A Clear Therapeutic VisionBuilding on Success: A Bright Future for Peptide Therapeutics
P50
Q21559667-E9D71D46-7EC7-4FA7-89D1-42E05A7AAC51Q24570085-CB0CE72A-6F49-460E-BA25-F1BB141E4599Q38452577-E1627A1E-34A6-4936-B45B-0629D5720154Q38742951-9DEAB81C-8DE7-48B3-824F-00E3124BCE5CQ38743021-4574D60B-11F6-45B6-BA0C-EB8614846C68Q38985869-297993DC-6EDB-48A9-A6C2-2BE9E5064047Q41953858-6C5B4ECA-5EB6-4884-97A9-9D49E7E75226Q42106861-23FF87CF-4217-4876-8881-4B8B946DADB0Q44009737-37D03726-43C6-4990-A6F0-DD0A2AE628B5Q44270779-FAD95329-4827-458B-9CF6-4EAA0FFD1148Q46322600-62E52993-43D6-4BB8-A8BA-DB61A82AE597Q47134297-E50F009F-887B-4E57-9A06-4330518366CAQ56031121-CC27AE49-EB95-4685-ACA4-37F7D46E44D6Q56031122-8A9D3FA1-CBAC-45B3-AE23-1ADE5B1A92FBQ57074492-A13387D6-0136-450B-883C-2F36E9BC75D1Q57074612-3CE25D45-FE20-48FC-B5D1-71A430AAC10FQ57074645-EC019C1C-6F11-4508-9049-5DC4A0F374D3Q57074732-8C1554D0-7127-43A5-A037-DD5A8654184DQ90702003-1AA10979-93D0-4169-97F3-F84E81B2514CQ91301878-B49B0DD9-7E0D-4F13-B3CE-209BC66005E6Q93089620-DE5DC8E6-D510-4AB2-B440-BF81BB1C872D
P50
description
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Walter H. Moos
@ast
Walter H. Moos
@en
Walter H. Moos
@es
Walter H. Moos
@nl
Walter H. Moos
@sl
type
label
Walter H. Moos
@ast
Walter H. Moos
@en
Walter H. Moos
@es
Walter H. Moos
@nl
Walter H. Moos
@sl
altLabel
Walter Moos
@en
prefLabel
Walter H. Moos
@ast
Walter H. Moos
@en
Walter H. Moos
@es
Walter H. Moos
@nl
Walter H. Moos
@sl
P108
P106
P1153
7006268012
P21
P31
P496
0000-0001-7244-811X